Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction
- PMID: 17328047
- DOI: 10.1002/art.22410
Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction
Abstract
Objective: The transforming growth factor beta superfamily member macrophage inhibitory cytokine 1 (MIC-1) is expressed upon macrophage activation, regulated by the p53 pathway, and linked to clinical events in atherosclerosis and cancer. Since rheumatoid arthritis (RA) shares similar etiopathologic mechanisms with the above diseases, we sought to determine the clinical utility of determining MIC-1 serum levels and MIC-1 genotype in the management of RA.
Methods: Ninety-one RA patients were recruited. Serum was collected from 83 of these patients and synovial biopsy samples were collected from the remaining 8 patients. Of the 83 patients from whom serum was collected, 61 were treated on an outpatient basis (defined as having nonsevere disease), and 22 patients went on to undergo hemopoietic stem cell transplantation (HSCT) (defined as having severe disease).
Results: Serum levels of MIC-1 were higher in RA patients and reflected disease severity independently of classic disease markers. MIC-1 was detected in rheumatoid synovial specimens, and allelic variation of MIC-1 was associated with earlier erosive disease and severe treatment-resistant chronic RA. Additionally, algorithms including serum and/or allelic variation in MIC-1 predicted response to HSCT, the presence of severe disease, and joint erosions.
Conclusion: Determination of serum levels of MIC-1 and MIC-1 genotype may be clinically useful in the management of RA as well as in selection of patients for HSCT, since they predict disease course and response to therapy. The data indicate a potential role for MIC-1 in RA pathogenesis. These results warrant larger prospective studies to fully delineate and confirm a role for MIC-1 genotyping and serum estimation in patient selection for HSCT and in the management of RA.
Similar articles
-
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.Arthritis Rheum. 2008 Aug;58(8):2257-67. doi: 10.1002/art.23667. Arthritis Rheum. 2008. PMID: 18668547
-
Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.Scand J Rheumatol. 2008 May-Jun;37(3):173-8. doi: 10.1080/03009740801898608. Scand J Rheumatol. 2008. PMID: 18465450
-
The status of stem cell transplantation for rheumatoid arthritis: a rheumatologist's view.J Rheumatol Suppl. 2001 Oct;64:60-1. J Rheumatol Suppl. 2001. PMID: 11642508 Review.
-
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.Arthritis Rheum. 2001 Sep;44(9):2055-64. doi: 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2. Arthritis Rheum. 2001. PMID: 11592367
-
[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis].Recenti Prog Med. 1995 Nov;86(11):456-62. Recenti Prog Med. 1995. PMID: 8539481 Review. Italian.
Cited by
-
Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.World J Gastroenterol. 2024 Apr 7;30(13):1899-1910. doi: 10.3748/wjg.v30.i13.1899. World J Gastroenterol. 2024. PMID: 38659482 Free PMC article.
-
Macrophage inhibitory cytokine-1 aggravates diet-induced gallstone formation via increased ABCG5/ABCG8 expression.PLoS One. 2023 Jun 13;18(6):e0287146. doi: 10.1371/journal.pone.0287146. eCollection 2023. PLoS One. 2023. PMID: 37310967 Free PMC article.
-
The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker.Int J Mol Sci. 2022 Oct 29;23(21):13180. doi: 10.3390/ijms232113180. Int J Mol Sci. 2022. PMID: 36361969 Free PMC article. Review.
-
Chrono-communication and cardiometabolic health: The intrinsic relationship and therapeutic nutritional promises.Front Endocrinol (Lausanne). 2022 Sep 13;13:975509. doi: 10.3389/fendo.2022.975509. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176473 Free PMC article. Review.
-
Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans.Elife. 2022 Aug 2;11:e76272. doi: 10.7554/eLife.76272. Elife. 2022. PMID: 35916366 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous